# Ezetimibe-Rosuvastatin Evaluation Study

> **NCT03947866** · — · UNKNOWN · sponsor: **Elpen Pharmaceutical Co. Inc.** · enrollment: 600 (estimated)

## Conditions studied

- Hypercholesterolemia
- Hyperlipidemias
- Combinations of Drugs; Dependence

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03947866
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-30
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947866, "Ezetimibe-Rosuvastatin Evaluation Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03947866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*